Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04331535 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Genomic Medicine at VA Study

Study acronym: GenoVA
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruitingv9 Show 4 more changesShow less
    • Enrollment target: estimated 1076 to confirmed 1071
    • Primary completion date changed from estimate of Sep 30, 2025 to Jan 31, 2026
    • Study completion date: Sep 30, 2025 to Sep 30, 2027
    • Site details revised
  2. Re-verified, no change to tracked fieldsv8
  3. Lead sponsor: Harvard Medical School (HMS and HSDM) to Boston VA Research Institute, Inc.v7
  4. Primary completion date: Mar 31, 2025 to Sep 30, 2025v6
  5. Primary completion date: Jan 31, 2024 to Mar 31, 2025
    • Study completion date: Jun 30, 2024 to Sep 30, 2025
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date changed from estimate of Jun 29, 2020 to Jul 17, 2020v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 1, 2020 to Jun 29, 2020
    • Site details revised
    • Publications: 149 to 152
    v3
  3. Start date: Apr 15, 2020 to Jun 1, 2020v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Boston VA Research Institute, Inc.
3 trials monitored
See all monitored trials
Heart Disease
8,786 trials monitored
See 412 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
and 5 more diseases
This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, atrial fibrillation, type 2 diabetes mellitus, colorectal cancer, breast cancer, or prostate cancer), measured by time-to-diagnosis of prevalent or incident disease over 24 months.
Trial Details
NCT Number NCT04331535
Lead Sponsor Boston VA Research Institute, Inc.
Collaborators: VA Boston Healthcare System
Conditions
(from sponsor)		 Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
Related terms Atrial Fibrillation, Breast Neoplasms, Colorectal Neoplasms, Coronary Artery Disease, Diabetes Mellitus, Type 2, Genetic Risk Score, Prostatic Neoplasms
Enrollment 1,071 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov